KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organon (OGN) Research & Development (2020 - 2026)

Organon has reported Research & Development over the past 7 years, most recently at $93.0 million for Q1 2026.

  • For Q1 2026, Research & Development fell 3.12% year-over-year to $93.0 million; the TTM value through Mar 2026 reached $363.0 million, down 15.97%, while the annual FY2025 figure was $366.0 million, 21.96% down from the prior year.
  • Research & Development for Q1 2026 was $93.0 million at Organon, up from $91.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $170.0 million in Q1 2024 and troughed at $27.0 million in Q2 2022.
  • A 5-year average of $110.9 million and a median of $116.0 million in 2024 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: tumbled 64.47% in 2022 and later skyrocketed 374.07% in 2023.
  • Year by year, Research & Development stood at $142.0 million in 2022, then fell by 5.63% to $134.0 million in 2023, then dropped by 2.99% to $130.0 million in 2024, then fell by 30.0% to $91.0 million in 2025, then grew by 2.2% to $93.0 million in 2026.
  • Business Quant data shows Research & Development for OGN at $93.0 million in Q1 2026, $91.0 million in Q4 2025, and $84.0 million in Q3 2025.